ArticleFrontiers in pharmacology2018
Annexin A1
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Annexin A1 as a Key Modulator of Inflammatory, Glial, and Angiogenic Signaling Pathways in Diabetic Retinopathy.Investigative ophthalmology & visual science · 2026Article
- ANXA1/FPR Signaling Contribute to Paclitaxel Resistance in Ovarian Cancer Through PI3K/AKT-Associated PGC1α Regulation.Cancer reports (Hoboken, N.J.) · 2026Article
- AcCells · 2025Article
- Innovative hydrogels in cutaneous wound healing: current status and future perspectives.Frontiers in bioengineering and biotechnology · 2025Review
- Advances in immunomodulation for organ transplantation: The role of the Annexin A1/FPR axis.Clinics (Sao Paulo, Brazil) · 2025Article
- The time-dependent expression of FPR2 and ANXA1 in murine deep vein thrombosis model and its relation to thrombus age.Forensic science, medicine, and pathology · 2024Article
- Homology-based identification and structural analysis ofComputational and structural biotechnology journal · 2024Article
- Development of Ac2-26 Mesoporous Microparticle System as a Potential Therapeutic Agent for Inflammatory Bowel Diseases.International journal of nanomedicine · 2024Article
- Overexpression of Annexin A1 is associated with the formation of capillaries in infantile hemangioma.Molecular and clinical oncology · 2022Article
- Review
- Effects of Formyl Peptide Receptor Agonists AcCells · 2022Article
- Mesoglycan connects Syndecan-4 and VEGFR2 through Annexin A1 and formyl peptide receptors to promote angiogenesis in vitro.The FEBS journal · 2021Article
- Annexin Animal Models-From Fundamental Principles to Translational Research.International journal of molecular sciences · 2021Review
- Article
- Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypothesis.Medical hypotheses · 2020Article
- Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.Molecular diagnosis & therapy · 2020Review
- Annexin A1/Formyl Peptide Receptor Pathway Controls Uterine Receptivity to the Blastocyst.Cells · 2020Article
- Inhibition of formyl peptide receptors improves the outcome in a mouse model of Alzheimer disease.Journal of neuroinflammation · 2020Article
- Annexin A1 May Induce Pancreatic Cancer Progression as a Key Player of Extracellular Vesicles Effects as Evidenced in the In Vitro MIA PaCa-2 Model System.International journal of molecular sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin graft successful depends on reduction of local inflammation evoked by the surgical lesion and efficient neovascularization to nutrition the graft. It has been shown that N-terminal portion of the Annexin A1 protein (AnxA1) with its anti-inflammatory properties induces epithelial mucosa repair and presents potential therapeutic approaches. The role of AnxA1 on wound healing has not been explored and we investigated in this study the effect of the peptide Ac2-26 (N-terminal AnxA1 peptide Ac2-26; AnxA1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.